Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

@article{Ogert2008MappingRT,
  title={Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.},
  author={Robert A. Ogert and Lisa Wojcik and Catherine A Buontempo and Lei Ba and Peter J Buontempo and Robert Ralston and Julie M Strizki and John A. Howe},
  journal={Virology},
  year={2008},
  volume={373 2},
  pages={387-99}
}
Several small molecule drugs that bind to the host CCR5 co-receptor and prevent viral entry have been developed for the treatment of HIV-1 infection. The innate variability found in HIV-1 envelope and the complex viral/cellular interactions during entry makes defining resistance to these inhibitors challenging. Here we found that mapping determinants in the gp160 gene from a primary isolate RU570-VCV(res), selected in culture for resistance to the CCR5 entry inhibitor vicriviroc, was… CONTINUE READING